Rachel Goss
Family · Terre Haute, INNPI 1508180639
Payments from drug & device makers
Across 284 payments — averaging $17.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$713
- AstraZeneca$621
- Novo Nordisk$483
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$466
- Amgen$449
- Novartis$397
- plus $2K from 28 others
What the payments were for
- Food & beverage$5,05099%
- Education$261%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 49 | $713 |
| AstraZeneca | 28 | $621 |
| Novo Nordisk | 23 | $483 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 33 | $466 |
| Amgen | 20 | $449 |
| Novartis | 19 | $397 |
| Otsuka America Pharmaceutical, Inc. | 21 | $359 |
| Eisai Inc. | 11 | $196 |
| Lundbeck LLC | 8 | $165 |
| Pfizer | 10 | $163 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $112 |
| Boehringer Ingelheim | 5 | $93 |
| Phathom Pharmaceuticals, Inc. | 4 | $80 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $62 |
| AbbVie | 4 | $59 |
| Corium, LLC | 4 | $54 |
| Idorsia Pharmaceuticals US Inc | 3 | $52 |
| Bayer | 3 | $50 |
| Alkermes, Inc. | 2 | $46 |
| Exact Sciences | 2 | $45 |
| Astellas Pharma US Inc | 3 | $44 |
| Axsome Therapeutics, Inc. | 2 | $44 |
| Biohaven Pharmaceuticals, Inc. | 2 | $43 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $43 |
| Sanofi-aventis U.S. LLC | 3 | $42 |
| Abbott | 2 | $40 |
| Merck | 2 | $27 |
| Exeltis, USA Inc. | 2 | $27 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Vanda Pharmaceuticals Inc. | 1 | $20 |
| GSK | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Adlon Therapeutics L.p. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,077 in reported general payments places this provider in the 90th percentile of 4,392 family providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 109 | $149,426 |
| JardianceEmpagliflozin | 141 | $127,273 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 131 | $110,651 |
| MounjaroTirzepatide | 86 | $105,926 |
| FarxigaDapagliflozin Propanediol | 97 | $85,139 |
| RexultiBrexpiprazole | 47 | $80,038 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 90 | $60,973 |
| EliquisApixaban | 77 | $49,940 |
| TrulicityDulaglutide | 22 | $39,167 |
| EntrestoSacubitril/Valsartan | 44 | $32,479 |
| CaplytaLumateperone Tosylate | 13 | $21,117 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $17,608 |
| LinzessLinaclotide | 26 | $16,798 |
| MyrbetriqMirabegron | 18 | $13,195 |
| BelsomraSuvorexant | 13 | $6,677 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $483 | $149,426109 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $621 | $146,112187 claims |
| Lilly USA, LLCMounjaro, Trulicity | $713 | $145,093108 claims |
| Boehringer IngelheimJardiance | $93 | $127,273141 claims |
| GSKTrelegy Ellipta | $19 | $110,651131 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $359 | $80,03847 claims |
| PfizerEliquis | $163 | $49,94077 claims |
| NovartisEntresto | $397 | $32,47944 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $466 | $21,11713 claims |
| AbbVieLinzess | $59 | $16,79826 claims |
| Astellas Pharma US IncMyrbetriq | $44 | $13,19518 claims |
| MerckBelsomra | $27 | $6,67713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,392 family providers in Indiana.
Other family in Terre Haute
- Stephanie ArnoldTerre Haute$52K
- Daxton DuncanTerre Haute$31K
- Melinda FuquaTerre Haute$19K
- Tamara GormanTerre Haute$16K
- Kathy BannonTerre Haute$15K
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.